Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections (original) (raw)

Infections after Transplant

Bone Marrow Transplantation volume 34, pages 13–20 (2004)Cite this article

Summary:

Caspofungin, an echinocandin antifungal agent, is active against invasive Aspergillus and Candida infections. In a phase I study in healthy volunteers, mild transient increases in serum aminotransferases were observed with the concomitant administration of caspofungin and cyclosporin A (CsA). As a result, it is recommended that the concomitant use of the two drugs be limited to those settings with appropriate risk–benefit balance. We retrospectively assessed safety data in 14 patients with refractory invasive mycoses who were treated concomitantly with CsA and caspofungin before the drug was licensed in Spain. In all, 13 patients were adults (median age, 31.5 years; range, 14–67 years). The average duration of concomitant therapy was 15 days (range, 2–43 days). No clinically significant elevations of serum aminotransferases were observed, and no patient had concomitant therapy discontinued or interrupted due to a drug-related adverse event. In this study of a limited number of patients, the coadministration of caspofungin and CsA was generally well tolerated.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1

Similar content being viewed by others

References

  1. Deresinski SC, Stevens DA . Caspofungin. Clin Infect Dis 2003; 36: 1445–1457.
    Article CAS Google Scholar
  2. Maertens J, Raad I, Petrikkos G et al. Update of multicenter non-comparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90 patients. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). American Society for Microbiology: Washington, DC, 2002 (abstr. M-856).
    Google Scholar
  3. Mora-Duarte J, Betts R, Rotstein C et al. Caspofungin vs amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: a multi-centre, randomized, double-blind study. N Engl J Med 2002; 347: 2020–2029.
    Article CAS Google Scholar
  4. Cancidas (caspofungin acetate). Summary of Product Characteristics. Document European Public Assessment Report, The European Agency for the Evaluation of Medicinal Products, April 2003.
  5. Sable CA, Nguyen BYT, Chodakewitz JA, DiNubile MJ . Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transplant Infect Dis 2002; 4: 25–30.
    Article CAS Google Scholar
  6. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294–299.
    Article CAS Google Scholar
  7. Cancidas (caspofungin acetate). Scientific Discussion. European Public Assessment Report, The European Agency for the Evaluation of Medicinal Products, October 2001; Available at: http://www.eudra.org/humandocs/Humans/EPAR/caspofungin/caspofungin.htm.
  8. Caspofungin Acetate FDA Advisory Committee Meeting Background Document. 6 December 2000; Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3676b1_02.pdf.
  9. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
    Article CAS Google Scholar
  10. Sullivan KM . Graft vs host disease. In: Thomas ED, Blume KB, Forman SJ (eds.). Hematopoietic Cell Transplantation, 2nd edn. Blackwell Scientific Publications: Oxford, 1999; pp 515.
    Google Scholar
  11. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
    Article CAS Google Scholar
  12. Thye D, Kilfoil T, Kilfoil G, Henkel T . Anidulafungin: safety and pharmacokinetics in subjects receiving concomitant cyclosporine. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). American Society for Microbiology: Washington, DC, 2002 (abstr. A-1836).
    Google Scholar
  13. Townsend R, Herbert M, Wisemandle W, Bekersky I . Concomitant pharmacokinetics of cyclosporine and micafungin in healthy adult volunteers. J Clin Pharmacol 2002; 42: 1051–1071 (abstr. 15).
    Google Scholar
  14. Kaneko H, Yamato Y, Hashimoto T et al. Drug interactions of micafungin in vitro. Jpn J Chemother 2002; 50: 94–103.
    CAS Google Scholar
  15. White RJ, Thye D . Anidulafungin does not affect the metabolism of cyclosporin by human hepatic microsomes. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). American Society for Microbiology: Washington, DC, 2001 (abstr. A-35).
    Google Scholar
  16. Trenschel R, Trampenau C, Elmaagacli A et al. Caspofungin (CSF) after allogeneic stem cell transplantation (SCT): a single center experience of 16 patients (pts) treated for fever of unknown origin (FUO) or invasive mycosis (IM). Bone Marrow Transplant 2002; 29 (Suppl. 2): S246 (abstr. P855).
    Google Scholar
  17. Kartsonis N, Taylor A, Ngai A et al. Clinical experience of caspofungin and cyclosporin A in patients treated in caspofungin clinical trials. Conference Highlights – Focus on Fungal Infections. FOFI: Maui, HI, 2003 (abstr. 39).
    Google Scholar
  18. Marr K, Hachem R, Papanicolau G et al. Retrospective study of concomitant use of caspofungin with cyclosporin A (CsA) in patients treated during marketed use. Blood 2003; 102: 471a (abstr. 1717).
    Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Research, Merck Sharp and Dohme of Spain, Madrid, Spain
    C Sanz-Rodriguez
  2. Department of Hematology, Hospital Marqués de Valdecilla, Santander, Spain
    M Lopez-Duarte
  3. Department of Hematology, Hospital Virgen de las Nieves, Granada, Spain
    M Jurado
  4. Department of Hematology, Hospital Ramón y Cajal, Madrid, Spain
    J Lopez
  5. Department of Hematology, Hospital Universitario de la Princesa, Madrid, Spain
    R Arranz
  6. Department of Infectious Diseases, Hospital Universitario Virgen del Rocío, Sevilla, Spain
    J-M Cisneros
  7. Department of Hematology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
    M L Martino
  8. Department of Hematology, Hospital Clínico Universitario San Carlos, Madrid, Spain
    P J Garcia-Sanchez
  9. Department of Respiratory Diseases, Unit of Lung Transplant, Hospital Universitario La Fe, Valencia, Spain
    P Morales
  10. Department of Pediatrics, Unit of Hematology, Hospital Vall d'Hebron, Barcelona, Spain
    T Olivé
  11. Department of Hematology, Hospital Clínic i Provincial, Barcelona, Spain
    M Rovira
  12. Department of Hematology, Hospital Clínico Universitario, Valencia, Spain
    C Solano

Authors

  1. C Sanz-Rodriguez
  2. M Lopez-Duarte
  3. M Jurado
  4. J Lopez
  5. R Arranz
  6. J-M Cisneros
  7. M L Martino
  8. P J Garcia-Sanchez
  9. P Morales
  10. T Olivé
  11. M Rovira
  12. C Solano

Corresponding author

Correspondence toC Sanz-Rodriguez.

Rights and permissions

About this article

Cite this article

Sanz-Rodriguez, C., Lopez-Duarte, M., Jurado, M. et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections.Bone Marrow Transplant 34, 13–20 (2004). https://doi.org/10.1038/sj.bmt.1704516

Download citation

Keywords

This article is cited by